Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma

Abstract

Hepatic annexin A2 (ANXA2) orchestrates multiple biologic processes and clinical symptoms and plays a key role in development, metastasis, and drug resistance of lethal hepatocellular carcinoma (HCC). However, the prognostic significance of ANXA2 for HCC has not been elucidated up to now. In this study, ANXA2 was frequently found to be up-regulated in HCC tissues compared with benign liver disease (BLD) tissues, which was consistent with the results in serum samples and tissue specimens of patients with HCC. Furthermore, ANXA2 expression was significantly correlated with differentiated degree, intrahepatic metastasis, portal vein thrombus, and tumor node metastasis (TNM) staging. More importantly, increased ANXA2 level was first confirmed to be closely associated with shortened overall survival of HCC (χ (2) = 12.872, P = 0.005) and identified as an independent prognostic factor (hazard ratio 1.338, 95 % confidence interval (CI) 1.013 ~ 1.766, P = 0.040), suggesting that ANXA2 up-regulation might represent an acquired metastasis phenotype of HCC, help to screen out high-risk population for HCC, or more effectively treat a subset of postsurgical HCC patients positive for ANXA2.

Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

“…These results indicate that Annexin 2 may be an independent prognostic factor for hepatocellular carcinoma (20). Previous studies have demonstrated that the expression of Annexin A2 is significantly associated with metastasis and poor survival in nasopharyngeal and endometrial carcinoma, bladder cancer and serous ovarian cancer (21)(22)(23)(24).…”

Identification of chromatin‐accessible domains in non‐alcoholic steatohepatitis‐derived hepatocellular carcinoma

“…Several studies have demonstrated an up‐regulation of ANXA2 in human and experimental hepatocarcinogenesis, and have suggested that an elevated level of ANXA2 may be an independent serological marker for the early diagnosis of HCC . Furthermore, ANXA2 expression is significantly correlated with tumor stage and closely associated with overall survival of HCC patients …”

CACNA1B (Cav2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer

“…Statistical analysis was performed as described before [24]. Student's t -test was used to compare CACNA1B (Ca v 2.2) mRNA and protein expression between tumorous and nontumorous tissue samples.…”